在台湾人口中,更年期,更年期后激素治疗和胃潰瘍疾病之间的关联
Kuan-Chih Chen1, Chia-Yu Kuo2, Wan-Ling Tsai3
1Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
Scientific reports
|July 7, 2025
概括
绝经后的妇女患上胃潰瘍疾病 (PUD) 的风险更高. 手术性更年期显著增加了PUD风险,而自然更年期的激素治疗也提高了PUD患病率.
科学领域:
- 胃肠病学 胃肠病学
- 内分泌学 在内分泌学.
- 流行病学 流行病学
背景情况:
- 更年期与各种健康问题有关,但其与消化道,特别是胃病 (PUD) 的关联尚未得到充分研究.
- 有限的数据存在于月经停产前期和激素替代疗法对PUD发展的影响.
研究的目的:
- 在大量人群中调查更年期和胃潰瘍疾病 (PUD) 之间的关联.
- 检查不同类型的更年期 (自然与外科手术) 和更年期后激素治疗如何影响PUD风险.
主要方法:
- 一项以人口为基础的研究,利用台湾生物银行的17000多名参与者的数据.
- 更年期状态,使用激素替代疗法和PUD存在通过自我报告问卷来确定.
- 用二进制物流回归分析来评估相关性.
主要成果:
- 与绝经前妇女相比,绝经后妇女的PUD风险高1.19倍 (OR:1.19,95%CI:1.03-1.38).
- 手术性更年期与PUD有显著的关联 (OR: 1.38,95% CI: 1.16-1.63),而自然更年期没有 (OR: 1.12,95% CI: 0.96-1.30).
- 接受激素治疗的自然更年期妇女有更高的PUD患病率 (OR: 1.37,95%CI: 1.13-1.67),但没有发现手术更年期的这种联系.
结论:
- 更年期与患上胃病的风险增加有关.
- 与更年期相关的PUD风险似乎受到更年期的类型的影响,而手术更年期呈现出更明显的关联.
- 这些发现强调了在女性胃肠道健康研究中考虑更年期状态和类型的重要性.
相关概念视频
01:30Peptic Ulcer Disease I: Introduction
300
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
300
01:26Peptic Ulcer Disease IV: Management
148
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
148
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
593
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
593
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
555
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
555
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
600
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
600
01:28Peptic Ulcer Disease II: Pathophysiology
878
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
878